VolitionRx Limited (AMEX: VNRX) reported second-quarter 2026 financial results characterized by stable top-line performance and significant cost discipline. Quarterly revenue remained approximately $0.4 million, consistent with the same period in 2025. This figure aligns with the broader first-half 2026 revenue of $1.4 million, which represents 112 percent growth over the first half of 2025.

The company’s focus on operational efficiency yielded a 32 percent reduction in operating expenses compared to the second quarter of 2025, bringing total quarterly operating expenses to $4.6 million. This reduction was driven by savings from a cost-reduction program, including a 27 percent decrease in headcount compared to the same point in 2025. Consequently, the operating loss narrowed to $4.2 million, a 34 percent decrease from the comparable quarter last year. Net cash used in operating activities also improved, falling 18 percent to $5.2 million.

Financial Highlights

The net loss for the quarter was $7.3 million, an increase from $6.3 million in the same quarter of 2025. This increase was primarily due to non-cash accounting charges of approximately $3 million related to LIND convertible notes, partially offset by the $2.1 million reduction in operating expenses. Cash and cash equivalents at the end of the quarter totalled approximately $2.8 million, up from $1.1 million as at December 31, 2025.

Capital Raises and Business Updates

VolitionRx bolstered its liquidity position with $5.3 million in net proceeds during the quarter. This capital infusion included:

• $1.2 million from equity sales via its at-the-market facility.
• $4.1 million from the issuance of shares and warrants in a confidentially marketed public offering through Maxim Group.

On the business front, President and Group CEO Cameron Reynolds highlighted progress across multiple product pillars. The company is in discussions with more than a dozen leading diagnostic and liquid biopsy firms, aiming to secure licensing agreements that would generate upfront milestone payments, royalties, or recurring revenue.

Key developments include:

• A collaboration announcement with Sysmex Corporation, a global leader in in vitro diagnostics, where VolitionRx has successfully transferred its Nu.Q NETs assay onto Sysmex’s platform.
• Submission for peer review of a clinical manuscript on the Nu.Q® Vet feline prototype assay, which could unlock a $5 million contractual milestone payment upon publication. The assay demonstrated 97 percent specificity and 86 percent sensitivity in detecting feline lymphoma.
• Ongoing work with Hospices Civils de Lyon on reimbursement submissions for Nu.Q® Lung Cancer in France, with a pre-submission meeting held and a follow-up anticipated.
• Publication of the first peer-reviewed paper demonstrating its Capture-Seq™ liquid biopsy technology, which isolates greater than 99% pure circulating tumor-associated DNA.
• Progress on a lateral flow prototype assay for Nu.Q NETs, demonstrating correlation with the established CE Mark automated assay using finger-prick capillary blood samples.

What the Numbers Show

The divergence between flat quarterly revenue and substantial expense reductions indicates a strategic pivot toward margin preservation. While the top line remained static at approximately $0.4 million, the 32% drop in operating expenses to $4.6 million suggests that the cost reduction program is having an immediate impact on the bottom line. The simultaneous raise of $5.3 million in equity capital provides a buffer for ongoing R&D and commercialization efforts, particularly as the company targets high-value licensing deals in a total addressable market estimated at over $27 billion for human diagnostics and vet markets combined. The increase in net loss despite lower operating expenses highlights the impact of non-cash accounting charges related to convertible notes, rather than operational deterioration.

Conference Call Details

VolitionRx hosted a conference call to discuss these results on Friday, August 14 at 8:30 a.m. U.S. Eastern Time. The call was hosted by Louise Batchelor, Group Chief Marketing & Communications Officer, Cameron Reynolds, President and Group Chief Executive Officer, and Terig Hughes, Group Chief Financial Officer.

VolitionRx announced that results from its new lateral flow finger-prick prototype are highly correlated with those of its legacy automated Nu.Q® NETs test in critically ill sepsis patients. The findings suggest the potential for rapid, decentralized identification of high-risk patients in emergency rooms or at bedside settings.

The study, part of the SUMMIT program, compared H3.1 nucleosome measurements in capillary blood samples using the lateral flow device against plasma samples tested via the CE-marked laboratory assay. The two formats tracked closely, demonstrating significant feasibility for early detection of immune disruptions without requiring central laboratory infrastructure.

What the Numbers Show

The statistical alignment between the prototype and the established assay indicates strong validity for the new testing method. The data reveals a Spearman correlation of 0.85 and a Pearson correlation of 0.881. These figures confirm that the minimally invasive finger-prick sample yields results consistent with standard venous blood draws processed in centralized labs.

Dr Andrew Retter, Critical Care Lead and Medical Consultant at Volition, noted that the ability to quantify nucleosome levels using a simple lateral flow device could enable quicker clinical decision-making. He stated that this approach materially reduces barriers to testing and facilitates measurement at the bedside.

Market Expansion Strategy

Dr Gaetan Michel, Chief Operating Officer at Volition, highlighted the commercial implications of the technology. With approximately 166 million cases of sepsis worldwide and all-cause sepsis-related deaths representing 31.5% of total global deaths in 2021, the addressable market is substantial. The highest mortality burden exists in lower-middle-income countries where laboratory infrastructure is often weak or non-existent.

The company aims to leverage this technology to expand beyond traditional hospital infrastructure. Volition is actively targeting NGO partnerships and strategic collaborations with companies operating in low-income countries to accelerate commercialization. This decentralized testing pathway allows the firm to penetrate underserved regions effectively.

Previous announcements from Volition had already demonstrated correlation between whole venous blood samples using the lateral flow prototype and the established automated assay. More recently, the company confirmed successful detection of nucleosomes in capillary blood. This latest study validates the use of both capillary and plasma blood samples from intensive care patients, reinforcing the versatility of the test across various settings including doctor's offices, emergency departments, and home self-tests.